Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma
Public ClinicalTrials.gov record NCT01189253. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
TRUSTS: A Phase IIB/III Multicenter Study Comparing the Efficacy of TRabectedin Administered as a 3-Hour or 24-Hour Infusion to Doxorubicin in Patients With Advanced or Metastatic Untreated Soft Tissue Sarcoma
Study identification
- NCT ID
- NCT01189253
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Network
- Enrollment
- 133 participants
Conditions and interventions
Conditions
Interventions
- doxorubicin hydrochloride Drug
- laboratory biomarker analysis Other
- quality-of-life assessment Procedure
- trabectedin Drug
Drug · Other · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2011
- Primary completion
- May 31, 2013
- Completion
- May 31, 2015
- Last update posted
- Aug 7, 2014
2011 – 2015
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sarcoma Oncology Center | Santa Monica | California | 90403 | — |
| Stanford Hospital and Clinics | Stanford | California | — | — |
| Holden Comprehensive Cancer Center at University of Iowa | Iowa City | Iowa | 52242-1002 | — |
| Dana Farber Institute | Boston | Massachusetts | 02115 | — |
| Massachussets General Hospital | Boston | Massachusetts | — | — |
| Methodist Estabrook Cancer Center | Omaha | Nebraska | 68114-4199 | — |
| Carolinas Hematology-Oncology Associates | Charlotte | North Carolina | 28203-4239 | — |
| Pennsylvania Oncology Hematology Associates, Incorporated - Philadelphia | Philadelphia | Pennsylvania | 19106 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01189253, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 7, 2014 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01189253 live on ClinicalTrials.gov.